Drugs / Ciforadenant
Trials 8
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 15 trials | ||||||
| Phase 1 | NCT04280328 | Feb 2020 → Sep 2021 | plasma cell myeloma | Corvus Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03454451 | Apr 2018 → Dec 2022 | castration-resistant prostate carcinoma, cervical cancer, colorectal cancer, endometrial cancer +9 | Corvus Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02655822 | Jan 2016 → Jun 2021 | castration-resistant prostate carcinoma, renal cell carcinoma | Corvus Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02764892 | Aug → Nov 2012 | Parkinson disease | Vernalis (R&D) Ltd | Completed | No outcome recorded |
| Phase 1 | NCT01634568 | Aug 2011 → Feb 2012 | Parkinson disease | Vernalis (R&D) Ltd | Completed | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT05501054 | Feb 2023 → Nov 2026 expected | renal cell carcinoma | M.D. Anderson Cancer Center | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT03337698 | Dec 2017 → Oct 2025 | non-small cell lung carcinoma | Hoffmann-La Roche | Terminated | No outcome recorded |
| Phase 1/2 | NCT02253745 | Jul 2013 → Mar 2014 | attention deficit-hyperactivity disorder | Vernalis (R&D) Ltd | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT03237988 Comparator | Jul → Sep 2017 | — | Corvus Pharmaceuticals, Inc. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 24
| Date | Issuer | Release |
|---|---|---|
| 2025-10-17 | Corvus Pharmaceuticals, Inc. | Results Corvus Pharmaceuticals Announces Presentation of Interim Data from the Phase 1b/2 Clinical Trial of Ciforadenant for Patients with Metastatic Renal Cell Cancer at the European Society for Medical Oncology (ESMO) Congress 2025 corvuspharma.com ↗
The median PFS is 11.04 months. |
| 2024-11-09 | Corvus Pharmaceuticals, Inc. | Results Corvus Pharmaceuticals Announces New Data Highlighting Potential of Ciforadenant to Overcome Immunotherapy Resistance in Metastatic Castration Resistant Prostate Cancer corvuspharma.com ↗
5 of 24 (21%) receiving combination therapy had PSA partial responses defined as PSA reductions >30%, compared to 1 of 11 (9%) receiving monotherapy |
| 2024-05-06 | Corvus Pharmaceuticals, Inc. | Results Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2024 Financial Results corvuspharma.com ↗
Interim Data from Ciforadenant Phase 1b/2 Trial in Front Line Renal Cell Cancer Exceeds Predefined Deep Response Threshold |
| 2023-06-29 | Corvus Pharmaceuticals, Inc. | Results Corvus Pharmaceuticals Presents New Ciforadenant Preclinical Data at the 2nd JCA-AACR Precision Cancer Medicine International Conference corvuspharma.com ↗ |
| 2020-11-09 | Corvus Pharmaceuticals, Inc. | Results Corvus Completes Enrollment in Phase 1 Study of CPI-006 for Patients with COVID-19 and Presents Study Data at 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting corvuspharma.com ↗
All four RCC patients remain on treatment from 2-11+ months and results, as of the November 4, 2020 cut-off date, include one partial response (RECIST) in a patient refractory to previous treatment with nivolumab, ipilimumab and cabozantanib. |
| 2020-09-17 | Corvus Pharmaceuticals, Inc. | Results New Data from Ciforadenant Phase 1b/2 Clinical Study Presented at ESMO Virtual Congress 2020 corvuspharma.com ↗ |
| 2020-05-29 | Corvus Pharmaceuticals, Inc. | Results Corvus Pharmaceuticals Presents Updated Clinical Data Supporting and Refining the Adenosine Gene Signature’s Ability to Identify Patients Likely to Respond to Treatment with Ciforadenant corvuspharma.com ↗
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies and the utilization of novel biomarkers to enhance patient selection, announced updated results from its Phase 1b/2 clinical trial of ciforadenant, its adenosine A2A receptor antagonist, in patients with advanced refractory renal cell carcinoma (RCC). |
| 2020-05-13 | Corvus Pharmaceuticals, Inc. | Results Corvus Pharmaceuticals to Present Data on Refinement of the Adenosine Gene Signature and Ciforadenant in Renal Cell Cancer at the ASCO20 Virtual Scientific Program corvuspharma.com ↗
The abstract related to the poster (#5025) is available now at https://meetinglibrary.asco.org/ . |
| 2020-02-13 | Corvus Pharmaceuticals, Inc. | Results Corvus Pharmaceuticals Presents Updated Clinical Data from its Phase 1b/2 Clinical Trial of Ciforadenant at the 2020 American Society of Clinical Oncology’s Genitourinary Cancers Symposium corvuspharma.com ↗
announced updated results from its Phase 1b/2 clinical trial of ciforadenant, an adenosine A2A receptor antagonist, in patients with metastatic castration resistant prostate cancer (mCRPC). |
| 2019-11-08 | Corvus Pharmaceuticals, Inc. | Results Corvus Pharmaceuticals Presents Updated Data from CPI-006 Phase 1/1b Clinical Trial at 2019 Society for Immunotherapy of Cancer (SITC) Annual Meeting corvuspharma.com ↗
Company also presents data supporting potential of Adenosine Gene Signature to serve as a biomarker to identify patients that are likely to respond to CPI-006 and ciforadenant |
| 2019-06-02 | Corvus Pharmaceuticals, Inc. | Results Corvus Pharmaceuticals Presents Initial CPI-006 Phase 1/1b Clinical Data at 2019 ASCO Annual Meeting corvuspharma.com ↗
Initial Results demonstrated dose-dependent disease control in patients with advanced, refractory disease when administered as a monotherapy and in combination with ciforadenant (CPI-444) |
| 2019-02-06 | Corvus Pharmaceuticals, Inc. | Results Corvus Presents Updated Biomarker and Clinical Results from Lead Pipeline Programs CPI-444 and CPI-006 at Immuno-Oncology 360° Conference corvuspharma.com ↗ |
| 2018-11-10 | Corvus Pharmaceuticals, Inc. | Results Corvus Pharmaceuticals Announces Updated Results from Ongoing Clinical Studies of Lead Programs, CPI-444 and CPI-006, at SITC 33rd Annual Meeting corvuspharma.com ↗
Updated results from its Phase 1/1b clinical trial of CPI-444 in patients with treatment-refractory renal cell carcinoma (RCC) demonstrated an overall survival (OS) of 88 percent at more than 20 months follow-up with CPI-444 administered in combination with atezolizumab. |
| 2018-10-22 | Corvus Pharmaceuticals, Inc. | Results Corvus Pharmaceuticals Announces New Data on Adenosine Gene Signature Biomarker Associated with Patient Response to CPI-444 at European Society for Medical Oncology (ESMO) 2018 Congress corvuspharma.com ↗
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies, today announced new data on a biomarker associated with patient response to therapy with CPI-444, an adenosine receptor antagonist. |
| 2018-10-03 | Corvus Pharmaceuticals, Inc. | Results Corvus Pharmaceuticals Announces Publication of Preclinical Results Highlighting Antitumor Activity of CPI-444 in Multiple Tumor Models both as Monotherapy and in Combination Studies corvuspharma.com ↗
today announced the publication of results of preclinical studies of CPI-444 demonstrating that it induces dose dependent anti-tumor responses as a monotherapy and in combination with anti-PD-1, anti-PD-L1 and anti-CTLA-4 therapies. |
| 2018-06-28 | Corvus Pharmaceuticals, Inc. | Results Corvus Pharmaceuticals Announces Publication of Preclinical Study Results Demonstrating CPI-444 Antitumor Activity as Monotherapy and in Combination with Anti-PD-1 Therapy in Cancer Immunology, Immunotherapy corvuspharma.com ↗
The data showed that CPI-444 administered as monotherapy suppressed tumor growth and improved survival in animal tumor models, and CPI-444 administered in combination with anti-PD-1 therapy dramatically improved antitumor immune responses over either agent used alone. |
| 2017-11-11 | Corvus Pharmaceuticals, Inc. | Results Corvus Pharmaceuticals Announces Updated Clinical Data from Phase 1/1b Study of CPI-444 and Biomarker Data for Potential Use in Patient Selection corvuspharma.com ↗
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology therapies, today announced updated clinical data from the renal cell carcinoma (RCC) expansion cohorts of its ongoing Phase 1/1b study of CPI-444 as a single agent and in combination with atezolizumab (TECENTRIQ ® ). |
| 2017-06-05 | Corvus Pharmaceuticals, Inc. | Results Corvus Pharmaceuticals Announces Interim Results Demonstrating Anti-Tumor Activity of CPI-444 in Renal and Lung Cancer Patients Resistant or Refractory to Prior PD-(L)1 Treatment corvuspharma.com ↗
The data showed that treatment with CPI-444 as a single agent and in combination with atezolizumab (Tecentriq®) resulted in anti-tumor activity in patients resistant or refractory to prior treatment with anti-PD-(L)1 antibodies and patients with PD-L1 negative tumors. |
| 2017-04-04 | Corvus Pharmaceuticals, Inc. | Results Corvus Pharmaceuticals Announces Interim Results from Ongoing Phase 1/1b Study Demonstrating Safety and Clinical Activity of Lead Checkpoint Inhibitor CPI-444 in Patients with Advanced Cancers corvuspharma.com ↗
today announced interim safety and efficacy results from its ongoing Phase 1/1b study. |
| 2017-01-10 | Corvus Pharmaceuticals, Inc. | Results Corvus Pharmaceuticals Announces Expansion of Renal Cell Carcinoma Cohort in Ongoing Phase 1/1b Clinical Study of Lead Checkpoint Inhibitor CPI-444 corvuspharma.com ↗
today announced that the protocol-predefined criteria for expansion has been reached for the cohort of patients with renal cell carcinoma treated with single-agent CPI-444 in the Company’s ongoing Phase 1/1b study. |
| 2016-11-11 | Corvus Pharmaceuticals, Inc. | Results Corvus Pharmaceuticals Announces Preliminary Phase 1/1b Clinical Data with Lead Checkpoint Inhibitor CPI-444 Demonstrating Safety and Evidence of Anti-Tumor Activity as a Single Agent in Patients with Advanced Refractory Cancers corvuspharma.com ↗ |
| 2016-10-10 | Corvus Pharmaceuticals, Inc. | Results Corvus Pharmaceuticals Announces Biomarker Findings from Phase 1/1b Study of Lead Oral Checkpoint Inhibitor CPI-444 Presented at ESMO 2016 Congress corvuspharma.com ↗
The data were presented today in a poster session by Ian McCaffery , Ph.D., vice president, Translational Sciences at Corvus, at the European Society for Medical Oncology (ESMO) 2016 Congress at the Bella Center in Copenhagen, Denmark . |
| 2016-09-25 | Corvus Pharmaceuticals, Inc. | Results Corvus Pharmaceuticals Announces Preclinical and Preliminary Clinical Biomarker Data of Lead Oral Checkpoint Inhibitor CPI-444 Presented at Second CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference corvuspharma.com ↗
We are very encouraged by the early data showing that CPI-444 is well tolerated and by the biomarker data indicating that treatment with CPI-444 as a single agent is associated with activation of T-cells detected in the blood. |
| 2016-04-19 | Corvus Pharmaceuticals, Inc. | Results Corvus Pharmaceuticals Announces Results of Preclinical Studies Demonstrating Enhanced Immune Responses and Anti-Tumor Activity with CPI-444, an Investigational Immuno-Oncology Therapy corvuspharma.com ↗
The studies demonstrated that CPI-444, a selective and potent inhibitor of the adenosine A2A receptor, was effective in stimulating various immune cells, generating anti-tumor immunity, suppressing tumor growth and delaying tumor progression in animal models of cancer. |
All press releases naming this drug 33 releases
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 10 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ciforadenant | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04280328 ↗ |
| Known as | CPI-444 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03237988 ↗ |
| Known as | V81444 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02253745 ↗ |
| Action | Inhibit | “Ciforadenant blocks adenosine from binding to the A2A receptor.” NCT02655822 ↗1“Adenosine A2a receptor antagonist” CHEMBL4297184 ↗ |
| Modality | Small molecule | “ciforadenant, an oral small molecule targeting the adenosine-A2A receptor” NCT02655822 ↗ |
| Route | Oral | “single oral dose of V81444” NCT01634568 ↗ |
| Target | ADORA2A | “Adenosine A2a receptor antagonist” CHEMBL4297184 ↗ |